Du är här


Basilea Pharmaceutica AG: Basilea's Chief Technology Officer Dr. Ingrid Heinze-Krauss to retire and Dr. Günter Ditzinger named as successor

Basilea Pharmaceutica AG / Basilea's Chief Technology Officer Dr. Ingrid
Heinze-Krauss to retire and Dr.Günter Ditzinger named as successor .
Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is
solely responsible for the content of this announcement.
Basel, Switzerland, August 28, 2015

- Basilea Pharmaceutica Ltd. (SIX: BSLN) reports today that Dr. Ingrid
Heinze-Krauss will retire after 15 years with the company. Basilea named Dr.
Günter Ditzinger, currently Head of Pharmaceutics, to succeed Dr.
Heinze-Krauss in the role of Chief Technology Officer and as a member of the
management committee effective February 1, 2016.

Dr. Ditzinger joined Basilea in 2002 as CMC Project Leader&Pharmaceutical
Development Manager. He was promoted in 2009 to Head of Pharmaceutics in
which position he led the pharmaceutical development and manufacturing group
and acted as Dr. Heinze-Krauss' deputy. Prior to joining Basilea, he held
various positions with increasing responsibility at Hoechst Marion Roussel in
Frankfurt, Germany and at Novartis Pharma AG in Basel, Switzerland.

Dr. Ditzinger holds a PhD in Pharmaceutical Technology from the Johann
Wolfgang Goethe University in Frankfurt/Main, Germany.

Ronald Scott, Basilea's Chief Executive Officer, commented: "We are very
pleased that Dr. Günter Ditzinger will assume the role of Chief Technology
Officer of the company following Dr. Ingrid Heinze-Krauss' retirement. Günter
has profound knowledge and broad experience in all aspects of technical
development and operations, from early stage development through the
commercial phase. Günter is also uniquely qualified as a deputy head and
longstanding member of the Technical Operations management team to succeed
Dr. Heinze-Krauss as Chief Technology Officer. Dr. Ingrid Heinze-Krauss
joined Basilea at its founding in 2000. She established Basilea's Technical
Operations department and has managed the group since 2004. We wish to
sincerely thank Ingrid for her commitment and valuable contributions to
Basilea's success during all these years."

About Basilea

Basilea Pharmaceutica Ltd. is a biopharmaceutical company developing products
that address increasing resistance and non-response to current treatment
options in the therapeutic areas of bacterial infections, fungal infections
and cancer. The company uses the integrated research, development and
commercial operations of its subsidiary Basilea Pharmaceutica International
Ltd. to discover, develop and commercialize innovative pharmaceutical
products to meet the medical needs of patients with serious and potentially
life-threatening conditions. Basilea Pharmaceutica Ltd. is headquartered in
Basel, Switzerland and listed on the SIX Swiss Exchange (SIX: BSLN).
Additional information can be found at Basilea's websitewww.basilea.com.


This communication expressly or implicitly contains certain forward-looking
statements concerning Basilea Pharmaceutica Ltd. and its business. Such
statements involve certain known and unknown risks, uncertainties and other
factors, which could cause the actual results, financial condition,
performance or achievements of Basilea Pharmaceutica Ltd. to be materially
different from any future results, performance or achievements expressed or
implied by such forward-looking statements. Basilea Pharmaceutica Ltd. is
providing this communication as of this date and does not undertake to update
any forward-looking statements contained herein as a result of new
information, future events or otherwise.

For further information, please contact:

| Media Relations Investor Relations |
| Peer Nils Schröder, PhD Barbara Zink, PhD, MBA |
| |
|Head Public Relations& Head Corporate Development |
|Corporate Communications |
|+41 61 606 1102 +41 61 606 1233 |
|media_relations@basilea.com investor_relations@basilea.com |
This press release can be downloaded fromwww.basilea.com.

Press release (PDF)


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Basilea Pharmaceutica AG via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.